It will be possible to vaccinate 70% of Russia’s population against the coronavirus infection by November 2021, director of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry Alexander Gintsburg said.
"If the entire global immune-biological industry is mobilized to manufacture any particular vaccine, say, Sputnik V, all production facilities in the United States, Europe, Asia, Russia will be able to manufacture 12%, 15% at the most of the necessary amount of the vaccine in a span of one year. Miracles don’t happen," he said in an interview with the Dok-Tok program on Russia’s TV Channel One.
We must work in all directions to vaccinate some 70% of the population by November," TASS cited Gintsburg as saying.
By today, three anti-coronavirus vaccines have been registered in Russia. They are Sputnik V (Gam-covid-vac), developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry, the world’s first vaccine against the novel coronavirus; Epivaccorona, an epitopic vaccine developed by the Vector State Research Center of Virology and Biotechnology; and CoviVac, developed by the Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Science. All the three are two-component vaccines.
